Dapivirine vaginal ring helped protect women against HIV in ASPIRE Phase III trial

A vaginal ring containing an ARV called dapivirine that women use for a month at a time was safe and helped protect against HIV in a large-scale clinical trial of women in Africa. HIV risk was reduced significantly more among the study's older participants, who also used the ring most consistently. The results of the ASPIRE study, together with results of a second Phase III trial, are a boost to HIV prevention efforts in women.